<DOC>
	<DOCNO>NCT02938962</DOCNO>
	<brief_summary>The objective study evaluate compare effect intravenous topical administration tranexamic acid revision hip arthroplasty blood loss , allogenic blood transfusion rate , length hospital stay perioperative complication .</brief_summary>
	<brief_title>Intravenous vs. Topical Tranexamic Acid Revision THA ( VITALITY-X )</brief_title>
	<detailed_description>This study use prospective randomize single-blinded study design . The study include one hundred sixty patient undergo revision total hip arthroplasty single institution ( Mount Sinai Hospital ( MSH ) , Toronto , ON , Canada ) . Tranexamic acid routinely administer single intravenous preoperative dose ( unless contraindicate ) revision hip arthroplasty case MSH since May 2012 . In study , participant randomize 2 treatment group : intravenous ( IV ) administration tranexamic acid ( TXA ) topical administration TXA . The IV administration group receive single 20mg/kg dose TXA prior skin incision . The topical administration group 100mL solution ( 3g TXA 100cc normal saline ) instill surgical field surgery . The primary outcome measure delta hemoglobin ( defined change hemoglobin preoperative measurement POD 0 , 1 , 2 , 3 , 5 ) . Secondary outcome analyze include intraoperative estimate blood loss , allogenic blood transfusion rate , length hospital stay postoperative complication .</detailed_description>
	<mesh_term>Blood Loss , Surgical</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Age ≥ 18 year time surgery . Consent transfusion blood bloodrelated product . No contraindication use tranexamic acid . Revision hip arthroplasty perform MSH . Indication surgery include osteolysis , component failure , prosthetic joint infection , aseptic/septic loosening , periprosthetic fracture , recurrent instability/dislocation , polyethylene wear abductor insufficiency . Revision hip arthroplasty procedure perform include acetabular component revision , femoral component revision , impaction bone grafting , proximal femoral allograft , proximal femoral replacement , removal hardware ( exclude head/liner exchange ) . Direct lateral ( transgluteal , Hardinge ) approach utilized , include augmentation extend trochanteric osteotomy ( ETO ) , trochanteric slide modify trochanteric slide . Age &lt; 18 year time surgery . Posterior ( Moore , Southern ) Anterior ( SmithPeterson ) operative approach utilized . Implantation surgical drain . Patients undergo isolated combination femoral head exchange , acetabular liner exchange abductor repair . Patients absolute contraindication tranexamic acid use include : Allergy TXA previous adverse reaction TXA/its constituent . Thrombolytic event &lt; 1 year prior surgery ( myocardial infarction , cerebrovascular accident , pulmonary embolus ) . Active thrombolytic event and/or lifelong anticoagulant . Known coronary artery disease . Renal failure serum creatinine &gt; 200µmol/L , creatinine clearance &lt; 50mL/min and/or dialysis patient . Patients disseminate intravascular coagulation . Patients currently use Oral Contraceptive medication . Patients relative contraindication tranexamic acid use deem inappropriate tranexamic acid administration Anesthesiology team , include : Thrombolytic event &gt; 1 year prior surgery ( myocardial infarction , cerebrovascular accident , pulmonary embolus ) . History cancer . Patients history acquire disturbance color vision . Clinical judgment Anesthesiology team otherwise specify . Patients ineligible refuse consent allogenic blood transfusion . Blood conservation augmentation strategy utilize : Cell saver/autotransfusion . Administration erythropoietin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>